See the published version of this preprint at BMC Pharmacology and Toxicology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Donghui Zheng
Affiliated Huai'an Hospital of Xuzhou Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Diabetic nephropathy (DN) causes the vast proportion of excess mortality for patients with diabetes. Novel therapeutic approaches slowing down its incidence is still lacking. Psoralen is the major active ingredient of Psoralea corylifolia Linn. (PCL), which was used to treat a number of diseases. In this study, we aimed to investigate whether psoralen could alleviate DN and to explore the underlying mechanisms.
Methods Cell viability assay and immunofluorescence were used to evaluate the effect of psoralen on high glucose (HG)-stimulated human kidney HK-2 cells. RT-qPCR was used to detect the expressions of miRNA in cells. Cell transfection, apoptosis assay and Western blot were further performed to explore the underlying molecular mechanisms.
Results Psoralen alleviated HG-induced viability decrease of HK-2 cells via inhibiting apoptosis. Meanwhile, the secretion of inflammatory cytokines and extracellular matrix (ECM) accumulation induced by HG in HK-2 cells were also decreased by psoralen. In addition, the expression of miR-874 in HK-2 cells was significantly upregulated by psoralen. Western blot assays indicated that psoralen inhibiting TGF-β1/Smad2 signaling via upregulation of miR-874.
Conclusion This study demonstrated that psoralen could significantly alleviate HG-induced HK-2 cell injury via upregulation of miR-874. Therefore, psoralen might serve as an agent for the treatment of DN.
Keywords
diabetic nephropathy, psoralen, miR-874, toll-like receptor-4, NF-κB, Smad2
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Pharmacology and Toxicology.
No community comments so far
Editor assigned
On 01 Jul, 2020
Submission checks complete
On 30 Jun, 2020
Editorial decision: Minor revision
On 30 Jun, 2020
Editor invited
On 30 Jun, 2020
Version 2
Posted 31 May, 2020
No comments provided
Editorial decision: Minor revision
On 23 Jun, 2020
Review #1 received
Received 09 Jun, 2020
Review #2 received
Received 30 May, 2020
Review #4 received
Received 25 May, 2020
Review #3 received
Received 25 May, 2020
Reviewer #3 agreed
On 23 May, 2020
Reviewer #4 agreed
On 23 May, 2020
Editor assigned
On 22 May, 2020
Reviewers invited
Invitations sent on 22 May, 2020
Reviewer #1 agreed
On 22 May, 2020
Reviewer #2 agreed
On 22 May, 2020
Submission checks complete
On 21 May, 2020
Editor invited
On 21 May, 2020
No comments provided
Editorial decision: Major revision
On 25 Apr, 2020
Review #2 received
Received 18 Apr, 2020
Review #1 received
Received 18 Apr, 2020
Review #4 received
Received 13 Apr, 2020
Review #5 received
Received 13 Apr, 2020
Reviewer #5 agreed
On 05 Apr, 2020
Reviewer #4 agreed
On 04 Apr, 2020
Reviewer #3 agreed
On 02 Apr, 2020
Review #3 received
Received 02 Apr, 2020
Reviewer #1 agreed
On 01 Apr, 2020
Reviewer #2 agreed
On 01 Apr, 2020
Editor assigned
On 31 Mar, 2020
Reviewers invited
Invitations sent on 31 Mar, 2020
Submission checks complete
On 27 Mar, 2020
Editor invited
On 27 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Pharmacology and Toxicology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Donghui Zheng
Affiliated Huai'an Hospital of Xuzhou Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Pharmacology and Toxicology.
No community comments so far
Editor assigned
On 01 Jul, 2020
Submission checks complete
On 30 Jun, 2020
Editorial decision: Minor revision
On 30 Jun, 2020
Editor invited
On 30 Jun, 2020
Version 2
Posted 31 May, 2020
No comments provided
Editorial decision: Minor revision
On 23 Jun, 2020
Review #1 received
Received 09 Jun, 2020
Review #2 received
Received 30 May, 2020
Review #4 received
Received 25 May, 2020
Review #3 received
Received 25 May, 2020
Reviewer #3 agreed
On 23 May, 2020
Reviewer #4 agreed
On 23 May, 2020
Editor assigned
On 22 May, 2020
Reviewers invited
Invitations sent on 22 May, 2020
Reviewer #1 agreed
On 22 May, 2020
Reviewer #2 agreed
On 22 May, 2020
Submission checks complete
On 21 May, 2020
Editor invited
On 21 May, 2020
No comments provided
Editorial decision: Major revision
On 25 Apr, 2020
Review #2 received
Received 18 Apr, 2020
Review #1 received
Received 18 Apr, 2020
Review #4 received
Received 13 Apr, 2020
Review #5 received
Received 13 Apr, 2020
Reviewer #5 agreed
On 05 Apr, 2020
Reviewer #4 agreed
On 04 Apr, 2020
Reviewer #3 agreed
On 02 Apr, 2020
Review #3 received
Received 02 Apr, 2020
Reviewer #1 agreed
On 01 Apr, 2020
Reviewer #2 agreed
On 01 Apr, 2020
Editor assigned
On 31 Mar, 2020
Reviewers invited
Invitations sent on 31 Mar, 2020
Submission checks complete
On 27 Mar, 2020
Editor invited
On 27 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Pharmacology and Toxicology.
Background Diabetic nephropathy (DN) causes the vast proportion of excess mortality for patients with diabetes. Novel therapeutic approaches slowing down its incidence is still lacking. Psoralen is the major active ingredient of Psoralea corylifolia Linn. (PCL), which was used to treat a number of diseases. In this study, we aimed to investigate whether psoralen could alleviate DN and to explore the underlying mechanisms.
Methods Cell viability assay and immunofluorescence were used to evaluate the effect of psoralen on high glucose (HG)-stimulated human kidney HK-2 cells. RT-qPCR was used to detect the expressions of miRNA in cells. Cell transfection, apoptosis assay and Western blot were further performed to explore the underlying molecular mechanisms.
Results Psoralen alleviated HG-induced viability decrease of HK-2 cells via inhibiting apoptosis. Meanwhile, the secretion of inflammatory cytokines and extracellular matrix (ECM) accumulation induced by HG in HK-2 cells were also decreased by psoralen. In addition, the expression of miR-874 in HK-2 cells was significantly upregulated by psoralen. Western blot assays indicated that psoralen inhibiting TGF-β1/Smad2 signaling via upregulation of miR-874.
Conclusion This study demonstrated that psoralen could significantly alleviate HG-induced HK-2 cell injury via upregulation of miR-874. Therefore, psoralen might serve as an agent for the treatment of DN.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...